DB:GEKA

Stock Analysis Report

Genomma Lab Internacional. de

Executive Summary

Genomma Lab Internacional, S.A.B. de C.V.

Snowflake

Fundamentals

Very undervalued with reasonable growth potential.

Share Price & News

How has Genomma Lab Internacional. de's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.3%

DB:GEKA

2.2%

DE Pharmaceuticals

0.2%

DE Market


1 Year Return

-4.3%

DB:GEKA

-9.7%

DE Pharmaceuticals

-10.0%

DE Market

GEKA outperformed the Pharmaceuticals industry which returned -9.9% over the past year.

GEKA outperformed the Market in Germany which returned -10.4% over the past year.


Share holder returns

GEKAIndustryMarket
7 Day-1.3%2.2%0.2%
30 Day-12.9%6.6%-3.3%
90 Day-7.3%10.9%-3.9%
1 Year-4.3%-4.3%-6.6%-9.7%-7.1%-10.0%
3 Year-24.2%-24.2%-11.0%-18.6%11.3%1.7%
5 Year-64.8%-64.8%33.2%11.3%25.8%8.4%

Price Volatility Vs. Market

How volatile is Genomma Lab Internacional. de's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Genomma Lab Internacional. de undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Genomma Lab Internacional. de's share price is below the future cash flow value, and at a moderate discount (> 20%).

Genomma Lab Internacional. de's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Genomma Lab Internacional. de is good value based on earnings compared to the DE Pharmaceuticals industry average.

Genomma Lab Internacional. de is good value based on earnings compared to the Germany market.


Price Based on Expected Growth

Genomma Lab Internacional. de is good value based on expected growth next year.


Price Based on Value of Assets

Genomma Lab Internacional. de is good value based on assets compared to the DE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Genomma Lab Internacional. de expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

23.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Genomma Lab Internacional. de's revenue is expected to grow by 9.1% yearly, however this is not considered high growth (20% yearly).

Genomma Lab Internacional. de's earnings are expected to grow significantly at over 20% yearly.

Genomma Lab Internacional. de's revenue growth is expected to exceed the Germany market average.

Genomma Lab Internacional. de's earnings growth is expected to exceed the Germany market average.

Genomma Lab Internacional. de's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Genomma Lab Internacional. de is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Genomma Lab Internacional. de performed over the past 5 years?

2.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Genomma Lab Internacional. de's year on year earnings growth rate has been positive over the past 5 years.

Genomma Lab Internacional. de's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Genomma Lab Internacional. de's 1-year earnings growth is negative, it can't be compared to the DE Pharmaceuticals industry average.


Return on Equity

Genomma Lab Internacional. de has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Genomma Lab Internacional. de used its assets more efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Genomma Lab Internacional. de has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Genomma Lab Internacional. de's financial position?


Financial Position Analysis

Genomma Lab Internacional. de is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Genomma Lab Internacional. de's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Genomma Lab Internacional. de's level of debt (76.3%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (65.1% vs 76.3% today).

Debt is well covered by operating cash flow (20.3%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 4.1x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.7x debt.


Next Steps

Dividend

What is Genomma Lab Internacional. de's current dividend yield, its reliability and sustainability?

4.33%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Unable to evaluate Genomma Lab Internacional. de's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Genomma Lab Internacional. de's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Genomma Lab Internacional. de has not reported any payouts.

Unable to verify if Genomma Lab Internacional. de's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Genomma Lab Internacional. de has not reported any payouts.


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (3x coverage).


Next Steps

Management

What is the CEO of Genomma Lab Internacional. de's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Jorge Luis Brake Valderrama 0

0.9yrs

Tenure

0

Mr. Jorge Luis Brake Valderrama is the Chief Executive Officer at Genomma Lab Internacional SAB de CV since September 10, 2018. He held the position of Senior Vice President of Global Operations at Laureat ...


Management Age and Tenure

1.0yrs

Average Tenure

The average tenure for the Genomma Lab Internacional. de management team is less than 2 years, this suggests a new team.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Alejandro Bastón Patiño

    Executive Vice-President of Institutional Relations

    • Tenure: 0.0yrs
  • Antonio Zamora Galland

    Executive VP & CFO

    • Tenure: 0.0yrs
  • Jorge Luis Brake Valderrama

    Chief Executive Officer

    • Tenure: 0.9yrs
  • Juan Marco Sparvieri

    Executive VP & COO

    • Tenure: 1.0yrs
  • Santiago Alejandro Vélez Peláez

    Executive Vice-President of Industrial and R&D

    • Tenure: 0.0yrs
  • Ruben Alberto Luna Porres

    Legal Officer

    • Tenure: 0.0yrs
  • César Alejandro Jaramillo López

    Executive Vice President of Marketing

    • Tenure: 1.6yrs
  • Enrique Casillas

    Head of Investor Relations

    • Tenure: 0.0yrs
  • Leticia Campos Herrera

    Global Director of Human Resources - Genomma Experience

    • Tenure: 0.3yrs
  • Patricia Velázquez

    Chief of Security

    • Tenure: 0.0yrs

Board Members

  • Rodrigo Alonso Herrera Aspra

    Chairman of the Board of Directors

    • Tenure: 0.0yrs
  • Jorge Ricardo Gutiérrez Muñoz (75yo)

    Independent Director

    • Tenure: 0.0yrs
  • Juan Alonso

    Independent Director

    • Tenure: 0.0yrs
  • Renata Virginia Herrera Aspra

    Alternate Director

    • Tenure: 0.0yrs
  • Sabrina Lucila Herrera Aspra

    Proprietary Director

    • Tenure: 0.0yrs
  • Javier Vale Castilla

    Independent Director

    • Tenure: 0.0yrs
  • Ignacio González Rodríguez

    Independent Director

    • Tenure: 0.0yrs
  • Juan Carlos Gavito Aspe

    Independent Director

    • Tenure: 0.0yrs
  • Carlos Javier Vara Alonso

    Independent Director

    • Tenure: 1.6yrs
  • Burkhard Wittek

    Director

    • Tenure: 1.6yrs

Company Information

Genomma Lab Internacional, S.A.B. de C.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genomma Lab Internacional, S.A.B. de C.V.
  • Ticker: GEKA
  • Exchange: DB
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Mex$15.850b
  • Listing Market Cap: Mex$720.851m
  • Shares outstanding: 1.01b
  • Website: https://www.genommalab.com

Number of Employees


Location

  • Genomma Lab Internacional, S.A.B. de C.V.
  • Antonio Dovali Jaime # 70
  • Piso 2 Torre C
  • Mexico City
  • Distrito Federal
  • 1210
  • Mexico

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LAB BBMV (Bolsa Mexicana de Valores)YesSeries B Variable SharesMXMXNJun 2008
GEKADB (Deutsche Boerse AG)YesSeries B Variable SharesDEEURJun 2008
GNML.FOTCPK (Pink Sheets LLC)YesSeries B Variable SharesUSUSDJun 2008

Biography

Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the research, development, and marketing of pharmaceutical, over the counter, and cosmetic products in Mexico and intern ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 21:10
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.